Medica and Integral Diagnostics Limited Establish Joint Venture, MedX

Medica and Integral Diagnostis Limited partnership is an equal joint venture (JV) partnership, where MedX is to provide teleradiology reporting services and increased reporting capacity in Australia, New Zealand, the UK, and Ireland.

The primary short-term focus will be for MedX to provide access to a pool of dual-qualified radiologists who are able to operate in both markets and will support both companies’ acute, out-of-hours reporting services. The two partners will also collaborate in areas of mutual interest, including the deployment of augmented intelligence (AI) solutions.

In the future, there will be potential to expand the scope of the JV, including combining Integral Diagnostics’ existing reporting capabilities and resources with Medica’s experience in teleradiology, meaning MedX will have the potential to bid directly for teleradiology reporting contracts using its combined network of reporters. In time, there is also the potential for MedX to leverage its scalable and secure operating model and reporting system to offer its services outside of its core markets (UK, Ireland, Australia, and New Zealand).

MedX will be registered in Australia and the Board will comprise Integral Diagnostics’ CEO, Dr. Ian Kadish, and Chief Financial and Commercial Officer, Anne Lockwood, as well as Medica’s CEO, Stuart Quin, and CFO, Richard Jones.

Dr. Stuart Quin, CEO Medica Group, commented: “Establishing MedX in partnership with Integral Diagnostics will provide significant operational benefits for Medica for a modest investment and is testament to our continued desire to expand the geographic reach of our teleradiology services. Both companies share a joint culture underpinned by a focus on quality and an ambition to grow and develop our organizations. Medica will be able to capitalize on the JV’s shared expertise and market access to support the growth of our NightHawk reporting service and take advantage of the exciting teleradiology market opportunity in Australia, New Zealand and potential opportunities in other international markets.”

Dr. Ian Kadish, CEO of Integral Diagnostics Limited, commented: “Integral Diagnostics is pleased to enter this JV with one of the world’s premier teleradiology providers. MedX significantly enhances the capacity and reach of the JV partners and enables us to more comprehensively serve existing markets, as well as potentially to enter new markets. The JV partners share a culture committed to quality patient care and service, and we look forward to harnessing the JV for the benefit of our patients and referrers.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version